Affimed NV (Affimed NV) Cash-to-Debt : 3.77 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Affimed NV Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Affimed NV's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.77.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Affimed NV could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Affimed NV's Cash-to-Debt or its related term are showing as below:

AFMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.77 Med: 10.52 Max: 113.29
Current: 3.77

During the past 12 years, Affimed NV's highest Cash to Debt Ratio was 113.29. The lowest was 3.77. And the median was 10.52.

AFMD's Cash-to-Debt is ranked worse than
58.67% of 1539 companies
in the Biotechnology industry
Industry Median: 6.42 vs AFMD: 3.77

Affimed NV Cash-to-Debt Historical Data

The historical data trend for Affimed NV's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Affimed NV Cash-to-Debt Chart

Affimed NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

32.68

113.29

10.57

10.46

3.77

Affimed NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															10.46	9.32	7.88	4.63	3.77

Competitive Comparison of Affimed NV's Cash-to-Debt

For the Biotechnology subindustry, Affimed NV's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Affimed NV's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Affimed NV's Cash-to-Debt falls into.

Affimed NV Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Affimed NV's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	79.496	/	(6.949	+	14.154)
	=	3.77

Affimed NV's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	79.496	/	(6.949	+	14.154)
	=	3.77

Affimed NV (NAS:AFMD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Affimed NV Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Affimed NV's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Affimed NV (Affimed NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

A28:Germany

Address

Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120

Website

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.